Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients

Sponsor
Vanderbilt University (Other)
Overall Status
Completed
CT.gov ID
NCT02964026
Collaborator
Edwards Lifesciences (Industry)
6,844
2

Study Details

Study Description

Brief Summary

The primary objective for this retrospective Electronic Health Record (EHR) analysis is to evaluate the clinical outcomes associated with the utilization of a pulmonary artery catheter (PAC), for monitoring purposes, within patients undergoing cardiac surgeries (isolated coronary artery bypass graft [CABG], valve, aortic surgery, multi-procedures, other complex nonvalvular procedures and heart transplants). The study will be conducted using prospectively collected hospital inpatient data over a duration of over 5 years (Jan. 1, 2010

  • June 30, 2015) using a large US electronic health database (Cerner HealthFacts; Kansas City, MO).
Condition or Disease Intervention/Treatment Phase
  • Device: pulmonary artery catheter

Detailed Description

A retrospective study will be conducted using prospectively collected hospital inpatient data over a duration of over 5 years (Jan. 1, 2010 - June 30, 2015) using a large US electronic health database (Cerner HealthFacts; Kansas City, MO). Patients who underwent a qualifying cardiac surgery (verified through use of selected valid International Classification of Diseases-9 procedure codes and/or Current Procedural Terminology [CPT] codes) will be included. Each patient's cohort designation will be defined based upon whether he/she did or did not receive a pulmonary artery catheter (PAC) for monitoring purposes. Propensity scores, which take into account patient and hospital demographics, patient comorbidities, surgical type (isolated coronary artery bypass graft [CABG], valve, aortic surgery, multi-procedures, other complex nonvalvular procedures and heart transplants), and pre-operative condition (via an adapted EuroSCORE II) will be utilized to "match" patients who received a PAC for monitoring purposes with those who did not, to form a matched study cohort. Clinical outcomes will be monitored through index visit discharge and up to 90 days post index visit discharge.

Study Design

Study Type:
Observational
Actual Enrollment :
6844 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Retrospective Analysis of Clinical Outcomes Associated With Use of the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients Within the Cerner HealthFacts Database
Study Start Date :
Sep 1, 2016
Actual Primary Completion Date :
Nov 1, 2016
Actual Study Completion Date :
Nov 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Pulmonary artery catheter (PAC)

Patients received a PAC for monitoring purposes

Device: pulmonary artery catheter
PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
Other Names:
  • Swan-Ganz catheter
  • No pulmonary artery catheter (PAC)

    Patients did not receive a PAC for monitoring purposes

    Outcome Measures

    Primary Outcome Measures

    1. Hospital mortality during index visit [Admission through up to 180 days (hospital discharge)]

    2. Hospital length-of-stay (LOS) [Admission through up to 180 days (hospital discharge)]

      Index hospital visit LOS

    3. Hospital readmission [Through 30 days]

      Rate of hospital readmissions

    4. Hospital readmission [Through 60 days]

      Rate of hospital readmissions

    5. Hospital readmission [Through 90 days]

      Rate of hospital readmissions

    6. Major Adverse Cardiac Events (MACE) [Through 30 days]

    7. Major Adverse Cardiac Events (MACE) [Through 60 days]

    8. Major Adverse Cardiac Events (MACE) [Through 90 days]

    9. Major morbidity composite [Through 30 days]

    10. Major morbidity composite [Through 60 days]

    11. Major morbidity composite [Through 90 days]

    Secondary Outcome Measures

    1. New organ failure (cardiovascular, respiratory, coagulation, liver systems, renal) [Day 1 to discharge (up to 180 days)]

    2. Requirement for mechanical ventilation [Day 1 to discharge (up to 180 days)]

    3. Hemorrhage requiring blood transfusion [Day 1 to discharge (up to 180 days)]

    4. Acute kidney injury (KDIGO staging) [Day 1 to day 10]

    5. Infectious complications [Day 1 to discharge (up to 180 days)]

    6. Gastrointestinal complication (hepatic) [Day 1 to discharge (up to 180 days)]

    7. Respiratory failure [Day 1 to discharge (up to 180 days)]

    8. Sequential Organ Failure Assessment (SOFA) scores [Day 1 to discharge (up to 180 days)]

    9. Neurologic complication [Day 1 to discharge (up to 180 days)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient undergoes a qualifying cardiac surgery between Jan 1, 2010 and January 1,
    1. If multiple qualifying surgeries are present, the first in database will be utilized
    • Inpatient with a LOS of at least 48 hours

    • Treated arm receives a PAC for monitoring purposes within admission date and qualifying cardiac surgical day plus one via specified ICD-9 or CPT-4 codes, or EHR recorded PAC readings

    Exclusion Criteria:
    • Cardiac surgery patients with age <18 years on index procedure date

    • Non-treated arm derived from an institution which does not have database documented use of ICD-9 or CPT-4 PAC placement codes for monitoring purposes [Lessens the likelihood that the untreated arm is indeed treated by ensuring that the patient would likely be coded if he/she had a PAC in place for monitoring purposes]

    • Patient record must have the demographics populated of age, gender, and race. ICD-9 diagnosis and procedure codes must be present in record for index visit, as well as medications administered over index visit

    • Patient must be treated at a hospital which performs a minimum of 100 qualifying cardiac procedures per year

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Vanderbilt University
    • Edwards Lifesciences

    Investigators

    • Principal Investigator: Andrew D Shaw, MB, FRCA, FFICM, FCCM, Vanderbilt University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Andrew Shaw, Professor and Executive Vice Chair Department of Anesthesiology Executive Medical Director, Perioperative Services, Vanderbilt University
    ClinicalTrials.gov Identifier:
    NCT02964026
    Other Study ID Numbers:
    • 161377
    First Posted:
    Nov 15, 2016
    Last Update Posted:
    Feb 17, 2017
    Last Verified:
    Feb 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Andrew Shaw, Professor and Executive Vice Chair Department of Anesthesiology Executive Medical Director, Perioperative Services, Vanderbilt University

    Study Results

    No Results Posted as of Feb 17, 2017